Radiopharm Theranostics Limited · ASX:RAD
Radiopharm Theranostics — Investor Presentation (June 2026)
41 slides from Radiopharm Theranostics's investor presentation, June 2026
Slide 1: A Multi-Asset, First-in-Class Radiopharmaceutical Platform
NASDAQ: RADX / ASX: RAD A Multi-Asset, First-in-Class Radiopharmaceutical Platform Protein-engineered radiotherapies targeting validated oncology pathways COMPANY PRESENTATION June 2026
Slide 2: Notice & Disclaimer
Notice & Disclaimer The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Radiopharm Theranostics Ltd ACN 647 877 889
Slide 3: Investment Highlights
INVESTMENT HIGHLIGHTS BUILDING ONE OF THE MOST DIFFERENTIATED RADIOPHARMA PIPELINES Four clinical-stage Protein-engineered Clinically proven emitter RADIOTHERAPEUTICS MOLECULES ISOTOPES across PDL1; HER2; B7H3; KLK3 Very solid supply chain First in class targets Designed for superior with validate
Slide 4: Radiopharma Is Entering Its Second Wave
RADIOPHARMA IS ENTERING ITS SECOND WAVE The first wave proved radiopharma works — the second wave will be won by better delivery and new targets FIRST WAVE (validated by Novartis) LIMITATIONS Lutathera & Pluvicto established Kidney toxicity limits dose escalation radiopharma as effective therapy (pe
Slide 5: Radiopharma Consolidation Creates a Clear Exit Pathway
RADIOPHARMA CONSOLIDATION CREATES A CLEAR EXIT PATHWAY Large pharma actively acquiring radiopharma pipelines to expand beyond first-wave assets OBJECTIVE TARGET COMPANY EXAMPLES VERTICALLY INTEGRATED COMPANIES Novartis AAA FIRST WAVE INFRASTRUCTURE BMS RayzeBio Manufacturing (CDMO capabilities) BUIL
Slide 6: Our Core Platform: Protein-Engineered Radiotherapeutics
OUR CORE PLATFORM: PROTEIN-ENGINEERED RADIOTHERAPEUTICS Designed to optimize tumor delivery and therapeutic index NANOBODY PLATFORM mAb PLATFORM Small size → enhanced tumor penetration Liver excretion → minimal kidney accumulation Rapid clearance → reduced background exposure Sustained tumor uptake
Slide 7: Leadership with Proven Radiopharma Track Record
LEADERSHIP WITH PROVEN RADIOPHARMA TRACK RECORD EXPERIENCED CLINICAL AND REGULATORY TEAM Clinical development Regulatory Riccardo Canevari Dr. Dimitris Voliotis CEO CMC Radiochemistry CMO Former Chief Commercial Officer Former Global Head Clinical Development Quality Preclinical at AAA, Novartis at
Slide 8: Therapeutic Pipeline – clinical-stage assets in high-value oncology targets
Therapeutic Pipeline – 4 clinical-stage assets in high-value oncology targets PROGRAM TARGET INDICATION ISOTOPE PRECLINICAL PHASE I PHASE II NOTES 2026 KEY CATALYSTS LEAD PROGRAM FIRST IN CLASS RADIOTHERAPY PHASE I DOSE ESCALATION COMPLETION IN RAD204 PD-L1 PD-L1+ solid tumors Lu177 Q4 Phase I in 4
Slide 9: RAD204 - First-in-class PD-L1 targeted radiotherapy
RAD 204 THERAPEUTIC RAD204 - First-in-class PD-L1 targeted radiotherapy Radiation delivered directly to PD-L1 expressing tumors Validated Immuno-Oncology Target Potential positioning: Post-IO NSCLC Multiple Solid Tumors EXPANDS A PROVEN IO TARGET INTO A NEW THERAPEUTIC MODALITY 9
Slide 10: Extending PD-L1 Targeting Beyond Current Modalities
RAD 204 THERAPEUTIC EXTENDING PD-L1 TARGETING BEYOND CURRENT MODALITIES Anti-PD-L1 Nanobody • High-affinity single-domain monoclonal antibody LINKER CANCER CELL TARGETING RADIOACTIVE • Targeting a different epitope vs Atezolizumab TARGET MOLECULE ISOTOPE PD-L1 Sd mAb 177Lu CHECKPOINT INHIBITORS RADI
Slide 11: RAD204: Phase I dose escalating trial
RAD 204 THERAPEUTIC RAD204: Phase I dose escalating trial Dosing Cohort 3 TRIAL DESIGN Phase 0 in every patient, to (Imaging with Imaging dose 10 (0.37 GBq) confirm IHC PDL1+ Primary Objectives 177Lu-RAD204) with SPECT Imaging o Safety and tolerability of 177Lu-RAD204 o Recommended ph2 dose of 177Lu
Slide 12: Clinical data Phase I
RAD 204 THERAPEUTIC Clinical data Phase I • First (30mCi) and Second Cohort (60mCi) completed; data from n=6 subjects released. • Tumor uptake confirmed in all the treated subjects. • The safety profile has been favorable, with few adverse events and no related SAEs observed. • Currently recruiting
Slide 13: RAD202: HER2-Targeted Radiotherapy
RAD 202 THERAPEUTIC RAD202: HER2-TARGETED RADIOTHERAPY Bringing radiotherapy to one of the largest targetable oncology populations HER2: one of the most established oncology target Not only HER2+ Expanding to HER2-low / very low populations Potential positioning: Post-Enhertu (trastuzumab deruxtecan
Slide 14: Extending HER2 Targeting Beyond Current Modalities
RAD 202 THERAPEUTIC EXTENDING HER2 TARGETING BEYOND CURRENT MODALITIES Anti-HER2 Nanobody • High-affinity single-domain antibody LINKER • Targeting a different epitope vs Trastuzumab CANCER CELL TARGETING RADIOACTIVE TARGET MOLECULE ISOTOPE HER2 Sd mAb 177Lu CURRENT THERAPIES RADIOTHERAPY ADVANTAGE
Slide 15: Phase I Dose Escalation with Favorable Safety Profile
RAD 202 THERAPEUTIC PHASE I DOSE ESCALATION WITH FAVORABLE SAFETY PROFILE First two cohorts completed with no DLTs Dose escalation ongoing (up to 130 mci) Early biodistribution confirms tumor targeting Primary Objectives (Phase 1, Treatment): Phase 0 in every patient, to (Imaging with Imaging dose 1
Slide 16: RAD202 Next Gen Formulation
RAD 202 THERAPEUTIC RAD202 NEXT GEN FORMULATION Second-generation molecule designed to improve therapeutic index SUV GOAL Removal of His-tag “tail” • Improve tumor-to-kidney ratio (~50% kidney reduction shown in animal study) • Maintain tumor affinity Rapid iteration to improve tumor-to-kidney ratio
Slide 17: Tumor Uptake Confirmed Across Multiple Cohorts
RAD 202 THERAPEUTIC TUMOR UPTAKE CONFIRMED ACROSS MULTIPLE COHORTS Higher Tumor Uptake in Breast Cancer indication; ~linear increase from DL1 to DL2 in non-Breast tumors SUV Absorbed Dose at C1 Absorbed Dose at C1 Absorbed Dose at C1 with 30 mCi with 75 mCi with 130 mCi (highest across different les
Slide 18: RAD202 Investment Case
RAD 202 THERAPEUTIC RAD202 INVESTMENT CASE • HER2 is one of the largest and most validated oncology targets • Radiotherapy introduces new mechanism of action • Platform enables continued optimization and improvement Best-in-class potential in a large, expanding patient population 18
Slide 19: RAD 402: Next-generation prostate radiotherapy beyond PSMA
RAD402 THERAPEUTIC RAD 202 utilizes an anti-HER2 Nanobody as a targeting moiety Intellectual Property RAD 402: Next-generation prostate radiotherapy beyond PSMA KLK3 (PSA) = highly specific prostate target Alternative to PSMA-based therapies Designed for • Post-Pluvicto • Potential earlier lines use
Slide 20: RAD 402 first in class KLK3 targeting mAb
RAD402 THERAPEUTIC RAD 402 first in class KLK3 targeting mAb Potential for improved selectivity vs PSMA approaches LINKER CANCER CELL TARGETING RADIOACTIVE TARGET MOLECULE ISOTOPE KLK3 mAb 161Tb Highly differentiated approach in Prostate Cancer Success Bar (Post Pluvicto settings) • KLK3 = prostate-
Slide 21: Relative Expression Levels
RAD402 THERAPEUTIC Addressing limitations of PSMA-based radiotherapy KLK3 cleaner target and more selective for Prostate Cancer vs PSMA Relative Expression Levels 21
Slide 22: Tb161 — Differentiated Radiotherapeutic Profile
Tb161 — DIFFERENTIATED RADIOTHERAPEUTIC PROFILE Dual emission radiotherapy • Beta radiation → cross-fire effect • Auger electrons → high local DNA damage • Result: 30% higher dose at same activity Potential for improved efficacy vs standard beta emitters (M Hofman et al, 2025)
Slide 23: RAD402 Clinical Status
RAD 402 THERAPEUTIC RAD402 CLINICAL STATUS First-in-class Tb161 clinical program (Company Sponsored) – Phase I dose escalation underway • First Patient dose in March 2026 Dose Level Dose Status Results • Phase I Dose Escalation Underway Phase I DL1 30 mCi (1.1 GBq) Recruiting (Treatment with • Targe
Slide 24: RAD 402 Investment Case
RAD 402 THERAPEUTIC RAD 402 INVESTMENT CASE KLK3 + Tb161 = next-generation prostate radiotherapy beyond PSMA limitations KLK3 specificity → highly selective target Tb161 → dual radiation mechanism Large prostate cancer market 24
Slide 25: RV01: B7H3-targeted radiotherapy with pan-tumor potential
RV01 THERAPEUTIC RAD 202 utilizes an anti-HER2 Nanobody as a targeting moiety Intellectual Property RV01: B7H3-targeted radiotherapy with pan-tumor potential • B7H3 is one of the most pursued next-generation oncology targets • Broad applicability NSCLC, prostate, breast, colorectal, ovarian, sarcoma
Slide 26: Large, underexploited target with broad expression
RV 01 THERAPEUTIC Clinical data– Current Study status Large, underexploited target with broad expression High tumor expression, limited normal tissue expression Increasing interest from multiple companies 26
Slide 27: RV01 (Betabart) First-In-Class Selective Anti-B7H3 in Clinical Development
RV 01 THERAPEUTIC RV01 (Betabart) First-In-Class Selective Anti-B7H3 in Clinical Development Targeting 4Ig - B7H3 with picomolar affinity Soluble, blood circulating 2Ig-B7H3 LINKER isoform acts as a potential pseudo- target decoy (sink) CANCER CELL TARGETING RADIOACTIVE TARGET MOLECULE ISOTOPE B7H3
Slide 28: Phase I Basket Trial Underway
RV 01 THERAPEUTIC PHASE I BASKET TRIAL UNDERWAY • First patient dosed (Feb 2026) Dose Level Dose Status Data Results Disclosed • Dose escalation ongoing Phase I DL1 35 mCi (1.1 GBq) Recruiting (Treatment with 177Lu-RV01) • Multiple tumor types enrolled DL2 70 mCi (2.2 GBq) Primary Objectives (Phase
Slide 29: Imaging Compounds
RADIOPHARM THERANOSTICS, IMAGING COMPOUNDS 29
Slide 30: Imaging Portfolio & Strategy
IMAGING PORTFOLIO & STRATEGY Imaging portfolio provides near-term value and optionality Clinical-stage diagnostics platform Potential: Standalone commercialization Complementary to therapeutics, Partnering opportunity without increasing capital intensity Strategic optionality Non-dilutive value crea
Slide 31: Imaging Pipeline
IMAGING PIPELINE MOLECULE PROGRAM TARGET INDICATION ISOTOPE PHASE I PHASE II NOTES Molecule Short Chain Fatty Phase 2b in US completed NCT06777433 Small RAD101 Brain Mets F18 30 pts/30 pts recruited 20-patient interim analysis released (03/’26) Acid Primary Endpoint read-out June ‘26 Peptide Pancrea
Slide 32: RAD101: First-in-class PET imaging agent for brain metastases
RAD 101 DIAGNOSTIC RAD101: First-in-class PET imaging agent for brain metastases RAD 101 (PIVALATE) SMALL MOLECULE Selectively targets fatty acid synthase: LINKER overexpressed in tumors but not normal brain cells CANCER CELL TARGETING RADIOACTIVE TARGET MOLECULE ISOTOPE Fatty acid oxidation pivalat
Slide 33: Strong Interim Phase 2b Clinical Signal
RAD 101 DIAGNOSTIC STRONG INTERIM PHASE 2b CLINICAL SIGNAL • 90% concordance with MRI (18/20 patients) • Improved detection in equivocal cases • Study fully recruited SUPPORTS PROGRESSION TOWARD PHASE III AND POTENTIAL COMMERCIALIZATION 33
Slide 34: Potential First-in-Class Diagnostic with Commercial Scale
RAD 101 DIAGNOSTIC POTENTIAL FIRST-IN-CLASS DIAGNOSTIC WITH COMMERCIAL SCALE ~300,000 patients/year (US), Potential >$500M annual sales (US) Potential first-in-class diagnostic with scalable adoption Clear pathway to monetization through partnering or commercialization Year Year Year Year Year Year
Slide 35: Why Invest Now
WHY INVEST NOW • Multiple catalysts + differentiated platform • 4 clinical programs progressing in parallel • Near-term readouts across pipeline • Imaging Phase IIb readout and potential monetization • Asymmetric opportunity with multiple shots on goal and near-term catalysts 35
Slide 36: Thank You
Thank You www.radiopharmtheranostics.com 36
Slide 37: Appendix
Appendix z= RAD RADIOPHARM THERANOSTICS, 37
Slide 38: Chairman and Board
Chairman and Board Paul Hopper Executive Chairman Ian Turner Hester Larkin Noel Donnelly • Founder of Radiopharm Theranostics Ltd. • 25 years experience as a life-sciences entrepreneur • Founder, Chairman, non-executive director or C E O of more than fifteen companies in the US, Australia a n d Asia
Slide 39: Isotope Selection and Supply Chain
Isotope Selection and Supply Chain Beta-Emitters: Best proven therapeutic index, secure and reliable sourcing 177-Lutetium 161-Terbium Beta Particles B e t a & Au g e r Particles Most used therapeutic isotope Innovative dual atomic particle functionality combining the benefits of Beta cross-fire eff
Slide 40: RAD301 — αvβ6-targeted imaging for pancreatic cancer
RAD301 — αvβ6-targeted imaging for pancreatic cancer • Integrin αvβ6 = highly expressed in PDAC • Potential application in: Early detection Disease monitoring 40
Slide 41: Potential best-in-class imaging performance
RAD 301 DIAGNOSTIC Potential best-in-class imaging performance RAD 301 (Trivehexin) PEPTIDE • RGD peptide (arginylglycylaspartic acid) • Integrin αvβ6 receptor antagonist • Design features include hydrophilicity to reduce non-specific uptake into undesired organs and LINKER increase clearance in pla
Radiopharm Theranostics — Investor Presentation (June 2026) on 6ix